(VIANEWS) – Shares of SEQUANA MEDICAL (BEL 20: SEQUA.BR) slid by a staggering 33.81% in 21 sessions from €4.91 to €3.25 at 14:22 EST on Thursday, after three consecutive sessions in a row of losses. BEL 20 is falling 1.36% to €3,719.69, following the last session’s upward trend.
SEQUANA MEDICAL’s last close was €3.27, 56.4% below its 52-week high of €7.50.
About SEQUANA MEDICAL
Sequana Medical NV develops and commercializes treatment of fluid overload in liver disease, cancer, and heart failure. The company's products include alfapump system, an implantable pump system for the treatment of refractory liver ascites and malignant ascites; Direct Sodium Removal (DSR) for the treatment of persistent congestion due to heart failure; and alfapump DSR, a fully implanted system for direct sodium removal therapy in patients with fluid overload due to heart failure. It operates in Belgium, Germany, France, Switzerland, and internationally. The company was founded in 2006 and is headquartered in Ghent, Belgium.
Earnings Per Share
As for profitability, SEQUANA MEDICAL has a trailing twelve months EPS of €-0.88.
Volume
Today’s last reported volume for SEQUANA MEDICAL is 3665 which is 80.96% below its average volume of 15202.
Moving Average
SEQUANA MEDICAL’s worth is way below its 50-day moving average of €5.12 and way under its 200-day moving average of €5.86.
Revenue Growth
Year-on-year quarterly revenue growth grew by 31.8%, now sitting on 923k for the twelve trailing months.
Yearly Top and Bottom Value
SEQUANA MEDICAL’s stock is valued at €3.25 at 14:22 EST, way below its 52-week high of €7.50 and way higher than its 52-week low of €2.90.
More news about SEQUANA MEDICAL (SEQUA.BR).
